TELA Bio logo

TELA Bio (TELA) Q1 2026 Earnings

TELA·Reported May 12, 2026·After market close

TELA Bio reported Q1 2026 revenue of $19.1M (+2.9% YoY), beat analyst consensus of $18.6M by $462.3K. Diluted EPS came in at $-0.21 (+16.0% YoY), missed the $-0.14 consensus by $0.07.

Revenue
$19.1Mbeat by $462.3K
Consensus: $18.6M
Diluted EPS
$-0.21missed by $0.07
Consensus: $-0.14
SEC

SEC Filings

Earnings release8-K · 0001104659-26-059393
Quarterly report10-Q · 0001104659-26-060234

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about TELA Bio's Q1 2026 earnings report.

TELA Bio (TELA) reported Q1 2026 earnings on May 12, 2026 after market close.

TELA Bio reported revenue of $19.1M and diluted EPS of $-0.21 for Q1 2026.

Revenue beat the consensus estimate of $18.6M by $462.3K. EPS missed the consensus estimate of $-0.14 by $0.07.

Compared to the same quarter a year prior, revenue grew 2.9% from $18.5M a year earlier and diluted EPS grew 16.0% from $-0.25.

You can read the 8-K earnings release (0001104659-26-059393) and the 10-Q periodic report (0001104659-26-060234) directly on SEC EDGAR. The filing index links above go to sec.gov.